

Telotristat (XERMELO)

Criteria for Use

Updated May 2025

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at the [PBM INTERnet](#) or [PBM INTRANet](#) site for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive telotristat.

- Patient has not been on a stable sandostatin analog (SSA) regimen defined as a long-acting release, depot or infusion pump for ≥ 3 months
- More than 12 watery BMs per day associated with volume contraction, dehydration or hypotension
- Evidence of enteric infection
- Eastern Cooperative Oncology Group Performance Status ≥ 2
- History of short bowel syndrome
- Moderate to severe hepatic impairment (Child-Pugh class B or C)
- Unmanageable drug-drug interaction
- Known pregnancy

Inclusion Criteria

The answers to all of the following must be fulfilled in order to meet criteria.

- Diagnosis of neuroendocrine tumor
- Diarrhea secondary to carcinoid syndrome, inadequately managed with somatostatin analog (SSA) therapy alone; can be used in combination with short-acting SSA

Additional Inclusion Criteria

- For females who can become pregnant: Pregnancy should be excluded prior to receiving telotristat
- For females who can become pregnant and males with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy

Prepared: August 2018. Updated May 2025 by Kelly Echevarria. Contact: Berni Heron, Pharm.D., BCOP, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services 10P4P
